Analysesdetails,includingimputationmethods,arepro- videdintheeAppendixin Supplement2. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes Original Investigation Research jama.com (Reprinted) JAMA November 7, 2023 Volume 330, Number 17 1633 Â© 2023 American Medical Association. All rights reserved. Downloaded from jamanetwork.com by F. Hoffmann - La Roche LTD user on 10/02/2024Results Baseline Characteristics This trial was conducted between October 19, 2020, and November 1, 2022. Overall, 2267 participants were assessed for trial eligibility, 1428 participants were randomized, and 1425 participants received at least 1 dose of the study treat- ment (Figure 1). Baseline demographics and clinical charac- teristics were similar across groups (overall mean age, 59 years; 824 [58%] women; mean diabetes duration, 14 years; mean HbA1c, 8.8%; mean body weight, 90.5 kg; mean fast- ing serum glucose, 157 mg/dL; and median insulin glargine dose, 46 IU/d [0.53 IU/kg/d]) (Table 1;e T a b l e5i nSupple- ment 2). Racial and ethnic groups within the US were well represented (13% of participants were Black and 53% were Hispanic). 